GLPwatch
Papers (9189)
Page 152 of 154, ranked by citation count.
- Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.
- Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.
- Response to the letter from Horowitz et al. to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.
- Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.
- Addressing patient concerns about the 'newness' and long-term safety of GLP-1 receptor agonists: A clinician's guide to counseling.
- Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.
- A new indication for semaglutide (Wegovy).
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
- [Dulaglutide and liraglutide compared].
- Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
- Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland.
- Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes".
- Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus.
- Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.
- Weight management medications for chronic use in 37 veterans affairs medical centers-A medication use evaluation.
- New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.
- Tirzepatide for weight reduction in people without diabetes.
- Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist.
- Empagliflozin and dulaglutide: community awareness project promotes improved access to newly funded medications for Pacific patients with type 2 diabetes.
- Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
- An alternative combination therapy for type 2 diabetes?
- [Liraglutide in the treatment of diabetes type 2].
- The Peptide Paradox in Pharmacology of Obesity.
- Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications.
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
- A second case of liraglutide-type localised amyloidosis.
- Comment on: "Relative Effectiveness and Safety of the GLP-1 Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics" [Letter].
- [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
- Comment on "Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes".
- [Incretin-based therapy for treating patients with type 2 diabetes].
- GLP-1 Receptor Agonists as Pharmacologic Treatment for Obesity After Spinal Cord Injury: Clinical Considerations.
- Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.
- Sémaglutide et tirzépatide : nouvel espoir dans le traitement de l’insuffisance cardiaque ?
- Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease.
- [Nephrology : what's new in 2025].
- GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease.
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.
- Comparative pharmacovigilance analysis of suicidality-related adverse events among GLP-1 and non-GLP-1 anti-obesity drugs in the FDA Adverse Event Reporting System.
- Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.
- Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.
- RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.
- Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council.
- Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia.
- Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs).
- Blamed but not at fault: Anti-obesity medication adverse effects misidentified as perioperative complications - a comprehensive review and medicolegal warning for anesthesiologists.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.
- [Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients].
- Semaglutide and tirzepatide: Oral cavity effects of weight-loss therapies.
- Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial".
- RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.
- ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
- Ischemic Colitis Associated With Tirzepatide Therapy in a Young Female Patient: A Case Report.
- New drugs 2015, part 3.
- Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: A population-based cohort study.
- In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide.
- First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.
- In response: Considerations regarding compounding pharmacies and GLP-1 agonists.
- Smile: saluto-metabolic interventions for life enhancement.
- Efficacy and safety profile of Glucagon-Like Peptide-1 Receptor Agonist in obese Type-2 diabetes patients from a private institution in Karachi.
- Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.